WAM
ENGNW icon

Wolverine Asset Management’s enGene Therapeutics Warrants ENGNW Stock Holding History

Wolverine Asset Management’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,223
Closed -$48K – 1762
2025
Q4 		$48K Sell
16,223
-43,208
-73% -$98.6K ﹤0.01% 1283
2025
Q3 		$42.2K Buy
+59,431
New +$45K ﹤0.01% 1213
2025
Q1 		– Sell
-15,889
Closed -$13.4K – 1625
2024
Q4 		$13.4K Buy
+15,889
New +$23.5K ﹤0.01% 1328
2024
Q3 		– Sell
-28,197
Closed -$33.6K – 1687
2024
Q2 		$33.6K Buy
28,197
+15,507
+122% +$49.6K ﹤0.01% 1208
2024
Q1 		$66K Buy
12,690
+7,057
+125% +$21.5K ﹤0.01% 1087
2023
Q4 		$4.79K Buy
+5,633
New +$4.33K ﹤0.01% 1475

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Wolverine Asset Management's ENGNW Position: Q1 2026 in Review

Wolverine Asset Management sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2026, closing a stake of 16,223 shares — an estimated $48K sold.

Wolverine Asset Management first reported a position in ENGNW in Q4 2023 and held it in 6 quarters. The position peaked at $66K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • Wolverine Asset Management reported no remaining enGene Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
  • Wolverine Asset Management sold 16,223 enGene Therapeutics Warrants shares in Q1 2026, an estimated $48K.
  • Wolverine Asset Management first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 6 quarters.
  • Wolverine Asset Management's enGene Therapeutics Warrants position peaked at $66K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.